Is EGFR really a therapeutic target in head and neck cancers?

被引：9

作者：

Agarwal, Vijay ^{[1
]}

Subash, Anand ^{[2
]}

Nayar, Ravi C. ^{[2
]}

Rao, Vishal ^{[2
]}

机构：

[1] HCG Canc Ctr, Dept Med Oncol, Bangalore, Karnataka, India

[2] HCG Canc Ctr, Dept Head & Neck Oncol, Bangalore, Karnataka, India

来源：

JOURNAL OF SURGICAL ONCOLOGY | 2019年 / 119卷 / 06期

关键词：

Cetuximab; concurrent chemotherapy; EGFR; immunotherapy; targeted; SQUAMOUS-CELL CARCINOMA; GROWTH-FACTOR RECEPTOR; MULTICENTER PHASE-II; PLUS CETUXIMAB; OPEN-LABEL; RECURRENT; ANTIBODIES; MUTATIONS; TRIAL;

D O I：

10.1002/jso.25387

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Epidermal growth factor receptor (EGFR) is overexpressed in 90% to 100% of squamous cell carcinoma of the head and neck (SCCHN). The overexpression of EGFR and its ligand transforming growth factor is associated with poorer survival. EGFR inhibitors such as Cetuximab (Erbitux) have shown a significant antitumoral effect in SCCHN and has improved locoregional control and as well as survival. Even though there was some success with Cetuximab, work with other EGFR inhibition has not been very fruitful and not really shown any promise. Mechanism of action of Cetuximab could be immune-mediated rather than EGFR inhibition and EGFR may not necessarily be a therapeutic target in SCCHN.

引用

页码：685 / 686

页数：2

共 19 条

[1] Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck [J].

Bonner, JA ;

Harari, PM ;

Giralt, J ;

Azarnia, N ;

Shin, DM ;

Cohen, RB ;

Jones, CU ;

Sur, R ;

Raben, D ;

Jassem, J ;

Ove, R ;

Kies, MS ;

Baselga, J ;

Youssoufian, H ;

Amellal, N ;

Rowinsky, EK ;

Ang, KK .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (06) :567-578

[2] Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck [J].

Cohen, EEW ;

Rosen, F ;

Stadler, WM ;

Recant, W ;

Stenson, K ;

Huo, DZ ;

Vokes, EE .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (10) :1980-1987

[3] Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck [J].

Cohen, EEW ;

Kane, MA ;

List, MA ;

Brockstein, BE ;

Mehrotra, B ;

Huo, DZ ;

Mauer, AM ;

Pierce, C ;

Dekker, A ;

Vokes, EE .

CLINICAL CANCER RESEARCH, 2005, 11 (23) :8418-8424

[4] Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFR [J].

Cohen, EEW ;

Lingen, MW ;

Martin, LE ;

Harris, PL ;

Brannigan, BW ;

Haserlat, SM ;

Okimoto, RA ;

Sgroi, DC ;

Dahiya, S ;

Muir, B ;

Clark, JR ;

Rocco, JW ;

Vokes, EE ;

Haber, DA ;

Bell, DW .

CLINICAL CANCER RESEARCH, 2005, 11 (22) :8105-8108

[5]

Feldman R, 2014, ANN ONCOL S4, V25, piv340

[6] Levels of TGF-α and EGFR protein in head and neck squamous cell carcinoma and patient survival [J].

Grandis, JR ;

Melhem, MF ;

Gooding, WE ;

Day, R ;

Holst, VA ;

Wagener, MM ;

Drenning, SD ;

Tweardy, DJ .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (11) :824-832

[7] The immunogenicity of humanized and fully human antibodies Residual immunogenicity resides in the CDR regions [J].

Harding, Fiona A. ;

Stickler, Marcia M. ;

Razo, Jennifer ;

DuBridge, Robert B. .

MABS, 2010, 2 (03) :256-265

[8] Gefitinib (ZD1839, IressaTM) as palliative treatment in recurrent or metastatic head and neck cancer [J].

Kirby, AM ;

A'Hern, RP ;

D'Ambrosio, C ;

Tanay, M ;

Syrigos, KN ;

Rogers, SJ ;

Box, C ;

Eccles, SA ;

Nutting, CM ;

Harrington, KJ .

BRITISH JOURNAL OF CANCER, 2006, 94 (05) :631-636

[9] Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck [J].

Lee, JW ;

Soung, YH ;

Kim, SY ;

Nam, HK ;

Park, WS ;

Nam, SW ;

Kim, MS ;

Sun, DI ;

Lee, YS ;

Jang, JJ ;

Lee, JY ;

Lee, SH ;

Yoo, NJ ;

Lee, SH .

CLINICAL CANCER RESEARCH, 2005, 11 (08) :2879-2882

[10] Low incidence of mutations in EGFR kinase domain in Caucasian patients with head and neck squamous cell carcinoma [J].

Loeffler-Ragy, J ;

Witsch-Baumgartner, M ;

Tzankov, A ;

Hilbe, W ;

Schwentner, I ;

Sprinzl, GM ;

Utermann, G ;

Zwierzina, H .

EUROPEAN JOURNAL OF CANCER, 2006, 42 (01) :109-111

← 1 2 →